Skip to main content
Clinical Trials/NCT06718842
NCT06718842RecruitingNot Applicable

Walking Program in Fatty Liver Children With Phenylketonuria: Response of Liver Enzymes

Cairo University1 site in 1 country40 target enrollmentStarted: September 15, 2024Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
40
Locations
1
Primary Endpoint
alanine transamianse

Study Overview

Brief Summary

phenylketonuria (commonly known as PKU) is an inherited disorder that increases the levels of a substance called phenylalanine in the blood. PKU is usually associated with many metabolic complication including non-alcoholic fatty liver

Detailed Description

this study will include PKU children sufferers 9n=40) with non-alcoholic fatty liver to be randomly assigned to group I (n=20) that will perform walking program (online supervised free walking that will be applied daily for eight weeks) or group II (N=20) that will act as waitlisted children

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
9 Years to 12 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •PKU children
  • •obese children
  • •fatty liver children (non-alcoholic fatty liver)

Exclusion Criteria

  • •cardiac children
  • •diabetic children
  • •neurogenic disorders
  • •respiratory and renal problems

Arms & Interventions

group I

Experimental

this Group I will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will perform walking program (online supervised free walking that will be applied daily for eight weeks)

Intervention: walking free online supervised program (Behavioral)

Group II

No Intervention

this Group II will include PKU children sufferers (n=20) with non-alcoholic fatty liver that will act a waitlisted children

Outcomes

Primary Outcomes

alanine transamianse

Time Frame: it will be assessed after eight weeks

it is a serum liver enzyme

Secondary Outcomes

  • aspartate tranaminase(it will be assessed after eight weeks)
  • Gamma-glutamyl Transferase(it will be assessed after eight weeks)
  • alkaline phosphatase(it will be assessed after eight weeks)
  • triglycerides(it will be assessed after eight weeks)
  • body mass index(it will be assessed after eight weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ali Mohamed Ali ismail

Department of Physical Therapy for Cardiovascular/Respiratory Disorder and Geriatrics, Faculty of Physical Therapy

Cairo University

Study Sites (1)

Loading locations...

Similar Trials